NCT03941262: Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy |
|
|
| Completed | 1 | 27 | US | SNK01, Avelumab, Bavencio, Pembrolizumab, Keytruda | NKGen Biotech, Inc. | Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Unresectable Carcinoma, Solid Tumor, Adult, Advanced Cancer, Advanced Solid Tumor | 02/23 | 02/23 | | |
